Skip to main content

Advertisement

SpringerLink
Log in

Diagnostic significance of elevated expression of HBME-1 in papillary thyroid carcinoma

  • Original Article
  • Published:
Tumor Biology

Abstract

This study examined the association between hector battifora mesothelial antigen-1 (HBME-1) expression and papillary thyroid carcinoma (PTC). A total of 206 patients were enrolled in the current study including 96 PTC patients and 110 patients with benign thyroid nodules (BTN). Immunohistochemistry (Envision) were performed to assess the expression of HBME-1. Receiver operating characteristic curve (ROC) curves were applied to evaluate the diagnostic tumor node metastasis (TNM) value of HBME-1. Specimens from 96 patients with PTC and 110 patients with BTC were reviewed. HBME-1 was positively immunostained in PTC tissue, which was significantly higher than that in BTN tissues (77.1 vs. 5.77 %, P < 0.05). Immunohistochemistry also identified that HBME-1 expression did not show any statistically significant differences based on gender, age, tumor size, TNM stage, and lymph node metastasis (P > 0.05). Importantly, HBME-1 expression was correlated with infiltration levels and differential levels in PTC (both P < 0.05). HBME-1 was found to have high sensitivity (94.5 %) and specificity (77.08 %) for PTC diagnosis. Moreover, HBME-1 had a high specificity (83.33 %) at identifying the differential levels of PTC, but a low sensitivity (22.92 %). The sensitivity and specificity of HBME-1 identifying the infiltration levels of PTC were, respectively, 72.70 and 72.00 %. HBME-1 was highly expressed in PTC tissues, and HBME-1 can serve as a potential biomarker in the diagnosis of PTC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Dinets A, Pernemalm M, Kjellin H, Sviatoha V, Sofiadis A, Juhlin CC, et al. Differential protein expression profiles of cyst fluid from papillary thyroid carcinoma and benign thyroid lesions. PLoS One. 2015;10(5):e0126472.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Grant CS. Papillary thyroid cancer: Strategies for optimal individualized surgical management. Clin Ther. 2014;36(7):1117–26.

    Article  PubMed  Google Scholar 

  3. Takahashi M, Saenko VA, Rogounovitch TI, Kawaguchi T, Drozd VM, Takigawa-Imamura H, et al. The foxe1 locus is a major genetic determinant for radiation-related thyroid carcinoma in Chernobyl. Hum Mol Genet. 2010;19(12):2516–23.

    Article  CAS  PubMed  Google Scholar 

  4. Kim SK, Park HJ, Hong IK, Chung JH, Eun YG. A missense polymorphism (rs11466653, met326thr) of toll-like receptor 10 (tlr10) is associated with tumor size of papillary thyroid carcinoma in the Korean population. Endocrine. 2013;43(1):161–9.

    Article  CAS  PubMed  Google Scholar 

  5. Boufraqech M, Fassassi C, Kebebew E. Tlr-10 polymorphism and papillary thyroid cancer: one more snp to consider? Endocrine. 2013;43(1):10–1.

    Article  CAS  PubMed  Google Scholar 

  6. Dinets A, Hulchiy M, Sofiadis A, Ghaderi M, Hoog A, Larsson C, et al. Clinical, genetic, and immunohistochemical characterization of 70 Ukrainian adult cases with post-Chernobyl papillary thyroid carcinoma. Eur J Endocrinol. 2012;166(6):1049–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Owonikoko TK, Hossain MS, Bhimani C, Chen Z, Kim S, Ramalingam SS, et al. Soluble fas ligand as a biomarker of disease recurrence in differentiated thyroid cancer. Cancer. 2013;119(8):1503–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Schmitt AC, Cohen C, Siddiqui MT. Paired box gene 8, hbme-1, and cytokeratin 19 expression in preoperative fine-needle aspiration of papillary thyroid carcinoma: diagnostic utility. Cancer Cytopathology. 2010;118(4):196–202.

    Article  CAS  PubMed  Google Scholar 

  9. Guerra A, Marotta V, Deandrea M, Motta M, Limone PP, Caleo A, et al. Braf (v600e) associates with cytoplasmatic localization of p27kip1 and higher cytokeratin 19 expression in papillary thyroid carcinoma. Endocrine. 2013;44(1):165–71.

    Article  CAS  PubMed  Google Scholar 

  10. de Matos LL, Del Giglio AB, Matsubayashi CO, de Lima FM, Del Giglio A, da Silva Pinhal MA. Expression of ck-19, galectin-3 and hbme-1 in the differentiation of thyroid lesions: Systematic review and diagnostic meta-analysis. Diagn Pathol. 2012;7:97.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Scognamiglio T, Hyjek E, Kao J, Chen YT. Diagnostic usefulness of hbme1, galectin-3, ck19, and cited1 and evaluation of their expression in encapsulated lesions with questionable features of papillary thyroid carcinoma. Am J Clin Pathol. 2006;126(5):700–8.

    Article  CAS  PubMed  Google Scholar 

  12. de Matos PS, Ferreira AP, de Oliveira FF, Assumpcao LV, Metze K, Ward LS. Usefulness of hbme-1, cytokeratin 19 and galectin-3 immunostaining in the diagnosis of thyroid malignancy. Histopathology. 2005;47(4):391–401.

    Article  PubMed  Google Scholar 

  13. Nga ME, Lim GS, Soh CH, Kumarasinghe MP. Hbme-1 and ck19 are highly discriminatory in the cytological diagnosis of papillary thyroid carcinoma. Diagn Cytopathol. 2008;36(8):550–6.

    Article  PubMed  Google Scholar 

  14. Cui W, Sang W, Zheng S, Ma Y, Liu X, Zhang W. Usefulness of cytokeratin-19, galectin-3, and hector battifora mesothelial-1 in the diagnosis of benign and malignant thyroid nodules. Clin Lab. 2012;58(7-8):673–80.

    PubMed  Google Scholar 

  15. Fadda G, Rossi ED, Raffaelli M, Pontecorvi A, Sioletic S, Morassi F, et al. Follicular thyroid neoplasms can be classified as low- and high-risk according to hbme-1 and galectin-3 expression on liquid-based fine-needle cytology. Eur J Endocrinol. 2011;165(3):447–53.

    Article  CAS  PubMed  Google Scholar 

  16. Cheung CC, Ezzat S, Freeman JL, Rosen IB, Asa SL. Immunohistochemical diagnosis of papillary thyroid carcinoma. Mod Pathol. 2001;14(4):338–42.

    Article  CAS  PubMed  Google Scholar 

  17. Mase T, Funahashi H, Koshikawa T, Imai T, Nara Y, Tanaka Y, et al. Hbme-1 immunostaining in thyroid tumors especially in follicular neoplasm. Endocr J. 2003;50(2):173–7.

    Article  PubMed  Google Scholar 

  18. Chung SY, Park ES, Park SY, Song JY, Ryu HS. Cxc motif ligand 12 as a novel diagnostic marker for papillary thyroid carcinoma. Head Neck. 2014;36(7):1005–12.

    Article  PubMed  Google Scholar 

  19. Beesley MF, McLaren KM. Cytokeratin 19 and galectin-3 immunohistochemistry in the differential diagnosis of solitary thyroid nodules. Histopathology. 2002;41(3):236–43.

    Article  CAS  PubMed  Google Scholar 

  20. Zintzaras E, Ioannidis JP. Hegesma: Genome search meta-analysis and heterogeneity testing. Bioinformatics. 2005;21(18):3672–3.

    Article  CAS  PubMed  Google Scholar 

  21. Carling T, Ocal IT, Udelsman R. Special variants of differentiated thyroid cancer: does it alter the extent of surgery versus well-differentiated thyroid cancer? World J Surg. 2007;31(5):916–23.

    Article  PubMed  Google Scholar 

  22. Faquin WC, Baloch ZW. Fine-needle aspiration of follicular patterned lesions of the thyroid: diagnosis, management, and follow-up according to national cancer institute (nci) recommendations. Diagn Cytopathol. 2010;38(10):731–9.

    PubMed  Google Scholar 

  23. Ohori NP, Wolfe J, Hodak SP, LeBeau SO, Yip L, Carty SE, et al. "Colloid-rich" follicular neoplasm/suspicious for follicular neoplasm thyroid fine-needle aspiration specimens: cytologic, histologic, and molecular basis for considering an alternate view. Cancer Cytopathology. 2013;121(12):718–28.

    Article  PubMed  Google Scholar 

  24. Nasr MR, Mukhopadhyay S, Zhang S, Katzenstein AL. Immunohistochemical markers in diagnosis of papillary thyroid carcinoma: utility of hbme1 combined with ck19 immunostaining. Mod Pathol. 2006;19(12):1631–7.

    Article  CAS  PubMed  Google Scholar 

  25. Lansoy-Kuhn C, Picquenot JM, Edet-Sanson A, Mechken F, Laberge-Le Couteulx S, Cornic M, et al. Relationship between the immunohistochemistry of the primary tumour and 18f-fdg-pet/ct at recurrence in patients with well-differentiated thyroid carcinoma. Nucl Med Commun. 2013;34(4):340–6.

    Article  CAS  PubMed  Google Scholar 

  26. Barut F, Onak Kandemir N, Bektas S, Bahadir B, Keser S, Ozdamar SO. Universal markers of thyroid malignancies: Galectin-3, hbme-1, and cytokeratin-19. Endocr Pathol. 2010;21(2):80–9.

    Article  CAS  PubMed  Google Scholar 

  27. Paunovic I, Isic T, Havelka M, Tatic S, Cvejic D, Savin S. Combined immunohistochemistry for thyroid peroxidase, galectin-3, ck19 and hbme-1 in differential diagnosis of thyroid tumors. APMIS. 2012;120(5):368–79.

    Article  CAS  PubMed  Google Scholar 

  28. Wu G, Wang J, Zhou Z, Li T, Tang F. Combined staining for immunohistochemical markers in the diagnosis of papillary thyroid carcinoma: Improvement in the sensitivity or specificity? J Int Med Res. 2013;41(4):975–83.

    Article  PubMed  Google Scholar 

  29. Saleh HA, Jin B, Barnwell J, Alzohaili O. Utility of immunohistochemical markers in differentiating benign from malignant follicular-derived thyroid nodules. Diagn Pathol. 2010;5:9.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Zhu X, Sun T, Lu H, Zhou X, Lu Y, Cai X, et al. Diagnostic significance of ck19, ret, galectin-3 and hbme-1 expression for papillary thyroid carcinoma. J Clin Pathol. 2010;63(9):786–9.

    Article  PubMed  Google Scholar 

  31. Nechifor-Boila A, Borda A, Sassolas G, Hafdi-Nejjari Z, Borson-Chazot F, Lifante JC, et al. Immunohistochemical markers in the diagnosis of papillary thyroid carcinomas: The promising role of combined immunostaining using hbme-1 and cd56. Pathol Res Pract. 2013;209(9):585–92.

    Article  CAS  PubMed  Google Scholar 

  32. Casey MB, Lohse CM, Lloyd RV. Distinction between papillary thyroid hyperplasia and papillary thyroid carcinoma by immunohistochemical staining for cytokeratin 19, galectin-3, and hbme-1. Endocr Pathol. 2003;14(1):55–60.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

We would like to acknowledge the reviewers for their helpful comments on this paper.

Author information

Authors and Affiliations

  1. Department of Ent Head and Neck Surgery, First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, 710061, People’s Republic of China

    Yang-Jing Chen, Rui-Min Zhao, Qian Zhao, Bai-Ya Li, Xiao Li & Xia Chen

  2. Department of Liver and Gallbladder Surgery, First Affiliated Hospital of Xi’an Jiaotong University, Yanta Xi Road No. 277, Xi’an, 710061, People’s Republic of China

    Qing-Yong Ma

Authors
  1. Yang-Jing Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rui-Min Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Qian Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Bai-Ya Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Qing-Yong Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Xiao Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Xia Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Qing-Yong Ma.

Ethics declarations

Conflict of interest

None.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chen, YJ., Zhao, RM., Zhao, Q. et al. Diagnostic significance of elevated expression of HBME-1 in papillary thyroid carcinoma. Tumor Biol. 37, 8715–8720 (2016). https://doi.org/10.1007/s13277-015-4169-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-015-4169-5

Keywords

Search

Navigation